The company’s financials have been in a slump for the past several years, but it reported growth in the second quarter of this year. New product launches are expected to sustain the uptick in growth in the company’s third quarter.
Here is how the company’s stock price breaks down by division:
• Interventional cardiology: 27.6 percent
• Pacemakers, defibrillators: 27.4 percent
• Endoscopy: 16.6 percent
• Peripheral interventions: 11.2 percent
• Urology and women’s health: 7.3 percent
• Neuromodulation: 7 percent
• Electrophysiology: 2.2 percent
• Divested businesses: 0.7 percent
More articles on gastroenterology:
5 gastroenterologists making the news
Menthol spray show to improve ADR, reduce peristalsis
3 ways gastroenterologists can demonstrate value
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.